Lowest Price Guaranteed
Slides
117
Last Updated
August 2026
View Count
5517
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
5.1. Executive Summary: Market Landscape
5.2. Executive Summary: Market Trends
5.3. Executive Summary: Market Forecast and Opportunity Analysis
6. INTRODUCTION
6.1. Chapter Overview
6.2. Classification of Vectors
6.2.1. Virus Vectors
6.2.1.1. Retrovirus Vectors
6.2.1.2. Lentivirus Vectors
6.2.1.3. Adeno-associated Virus Vectors
6.2.1.4. Adenovirus Vectors
6.2.1.5. Other Virus Vectors
6.2.1.5.1. Alphavirus
6.2.1.5.2. Foamy Virus
6.2.1.5.3. Simian Virus
6.2.1.5.4. Vaccinia Virus
6.2.1.5.5. Chimeric Virus Vectors
6.2.1.5.6. Herpes Simplex Virus
6.2.1.5.7. Sendai Virus
6.2.2. Non-Virus Vectors
6.3. Adeno-associated Virus Vectors
6.3.1. Structure and Design
6.3.2. Adeno-associated Virus Vector Life Cycle
6.3.3. Applications of Adeno-associated Virus Vectors
6.3.3.1. Gene Therapy
6.3.3.2. Vaccination
6.3.4. Advantages of Adeno-associated Virus Vectors
6.3.5. Challenges Related to Adeno-associated Virus Vectors
6.4. Concluding Remarks
7. ADENO-ASSOCIATED VIRUS VECTOR MANUFACTURERS: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Adeno-associated Virus Vector Manufacturers: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Type of Product Manufactured
7.2.5. Analysis by Type of Vector Manufactured
7.2.6. Analysis by Scale of Operation
7.2.7. Analysis by Type of Manufacturer
7.2.8. Analysis by Application Area
7.2.9. Analysis by Location of Vector Manufacturing Facility
8. ADENO-ASSOCIATED VIRUS VECTOR MANUFACTURING: TECHNOLOGIES / PLATFORMS LANDSCAPE
8.1. Chapter Overview
8.2. Adeno-associated Virus Vector Manufacturing: Technologies / Platforms Landscape
8.2.1. Analysis by Type of Vector Manufactured
8.2.2. Analysis by Type of Virus Vector Manufactured
8.2.3. Analysis by Scale of Operation
8.2.4. Analysis by End-use
8.3. Adeno-associated Virus Vector Manufacturing: Technology / Platform Providers Landscape
8.3.1. Analysis by Year of Establishment
8.3.2. Analysis by Company Size
8.3.3. Analysis by Location of Headquarters
8.3.4. Most Active Players: Analysis by Number of Technologies / Platforms
9. COMPANY COMPETITIVENESS ANALYSIS: ADENO-ASSOCIATED VIRUS VECTOR MANUFACTURERS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. Overview of Peer Groups
9.5. Company Competitiveness Analysis
9.5.1. Adeno-associated Virus Vector Manufacturers Headquartered in North America
9.5.2. Adeno-associated Virus Vector Manufacturers Headquartered in Europe
9.5.3. Adeno-associated Virus Vector Manufacturers Headquartered in Asia-Pacific and the Rest of the World
10. TECHNOLOGY COMPETITIVENESS ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Methodology
10.4. Overview of Peer Groups
10.5. Adeno-associated Virus Vector Technologies / Platforms: Competitiveness Analysis
10.5.1. Adeno-associated Virus Vector Technologies / Platforms Provided by Companies Headquartered in North America
10.5.2. Adeno-associated Virus Vector Technologies / Platforms Provided by Companies Headquartered in Europe and Asia-Pacific
11. COMPANY PROFILES: LEADING ADENO-ASSOCIATED VIRUS VECTOR MANUFACTURERS
11.1. Chapter Overview
11.2. Astellas Pharma
11.2.1. Company Overview
11.2.2. Vector Manufacturing Portfolio
11.3. Charles River Laboratories
11.3.1. Company Overview
11.3.2. Vector Manufacturing Portfolio
11.4. Cytiva
11.4.1. Company Overview
11.4.2. Vector Manufacturing Portfolio
11.5. Lonza
11.5.1. Company Overview
11.5.2. Vector Manufacturing Portfolio
11.6. Sanofi
11.6.1. Company Overview
11.6.2. Vector Manufacturing Portfolio
11.7. Thermo Fisher Scientific
11.7.1. Company Overview
11.7.2. Vector Manufacturing Portfolio
11.8. Wuxi AppTec
11.8.1. Company Overview
11.8.2. Vector Manufacturing Portfolio
12. CLINICAL TRIAL ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Adeno-associated Virus Vector Based Therapies: Clinical Trial Analysis
12.3.1. Analysis by Trial Registration Year
12.3.2. Analysis of Patients Enrolled by Trial Registration Year
12.3.3. Analysis by Trial Phase
12.3.4. Analysis of Patients Enrolled by Trial Phase
12.3.5. Analysis by Trial Status
12.3.6. Analysis of Patients Enrolled by Trial Status
12.3.7. Analysis by Target Patient Population
12.3.8. Analysis by Patient Gender
12.3.9. Analysis by Type of Sponsor / Collaborator
12.3.10. Analysis by Study Design
12.3.10.1. Analysis by Type of Patient Allocation Model Used
12.3.10.2. Analysis by Type of Trial Masking Adopted
12.3.10.3. Analysis by Type of Trial Intervention Model
12.3.10.4. Analysis by Trial Purpose
12.3.11. Most Active Players: Analysis by Number of Clinical Trials Sponsored / Collaborated
12.3.12. Analysis by Geography
12.3.12.1. Analysis of Clinical Trials by Geography
12.3.12.2. Analysis of Clinical Trials by Geography and Trial Status
12.3.12.3. Analysis of Patients Enrolled by Geography and Trial Status
12.3.12.4. Analysis of Clinical Trials by Geography, Trial Status and Trial Phase
13. PARTNERSHIPS AND COLLABORATIONS: ADENO-ASSOCIATED VIRUS VECTOR MANUFACTURERS
13.1. Chapter Overview
13.2. Partnership Models
13.3. Adeno-associated Virus Vector Manufacturers: Partnerships and Collaborations
13.3.1. Analysis by Year of Partnership
13.3.2. Analysis by Type of Partnership
13.3.3. Analysis by Year and Type of Partnership
13.3.4. Analysis by Type of Partner
13.3.5. Analysis by Scale of Operation
13.3.6. Analysis by Therapeutic Area
13.3.7. Analysis by Application Area
13.3.8. Most Active Players: Analysis by Number of Partnerships
13.4. Analysis by Geography
13.4.1. Analysis by Local and International Agreements
13.4.2. Analysis by Intracontinental and Intercontinental Agreements
14. PATENT ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Adeno-associated Virus Vector Market: Patent Analysis
14.3.1. Analysis by Patent Application Year
14.3.2. Analysis by Patent Publication Year
14.3.3. Analysis by Type of Patent and Publication Year
14.3.4. Analysis by Patent Jurisdiction
14.3.5. Analysis by CPC Symbols
14.3.6. Analysis by Type of Applicant
14.3.7. Leading Industry Players: Analysis by Number of Patents
14.3.8. Leading Non-Industry Players: Analysis by Number of Patents
14.3.9. Leading Patent Assignees: Analysis by Number of Patents
14.4. Patent Benchmarking Analysis
14.4.1. Analysis by Patent Characteristics
14.5. Patent Valuation
14.6. Leading Patents by Number of Citations
15. START-UP HEALTH INDEXING
15.1. Chapter Overview
15.2. Start-ups Developing Adeno-associated Virus Vector Based Therapies
15.2.1. Analysis by Location of Headquarters
15.3. Benchmarking of Start-ups
15.3.1. Analysis by Pipeline Strength
15.3.2. Analysis by Pipeline Maturity
15.3.3. Analysis by Indication Diversity
15.3.4. Analysis by Patent Strength
15.3.5. Analysis by Partnership Activity
15.3.6. Start-ups Health Indexing: Roots Analysis Perspective
16. OUTSOURCING: GO / NO-GO FRAMEWORK
16.1. Chapter Overview
16.2. Outsourcing: Go / No-Go Framework
16.3. Adeno-associated Virus Vector Developers Outsourcing: Go / No-Go Framework
16.3.1. Key Assumptions and Parameters
16.3.2. Methodology
16.3.3. Results and Interpretations
16.3.3.1. Adeno-associated Virus Vector Based Therapy Developers: Benchmarking of Small Companies
16.3.3.2. Adeno-associated Virus Vector Based Therapy Developers: Benchmarking of Mid-sized Companies
16.3.3.3. Adeno-associated Virus Vector Based Therapy Developers: Benchmarking of Large Companies
16.4. Concluding Remarks
17. MARKET IMPACT ANALYSIS
17.1. Chapter Overview
17.2. Market Drivers
17.3. Market Restraints
17.4. Market Opportunities
17.5. Market Challenges
17.6. Conclusion
18. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR MANUFACTURING MARKET
18.1. Chapter Overview
18.2. Assumptions and Methodology
18.3. Global Adeno-associated Virus Vector Manufacturing Market: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
18.3.1. Scenario Analysis
18.3.1.1. Conservative Scenario
18.3.1.2. Optimistic Scenario
18.4. Key Market Segmentations
19. ADENO-ASSOCIATED VIRUS VECTOR MANUFACTURING MARKET, BY SCALE OF OPERATION
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Adeno-associated Virus Vector Manufacturing Market: Distribution by Stage of Development
19.3.1. Adeno-associated Virus Vector Manufacturing Market for Commercial Scale: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
19.3.2. Adeno-associated Virus Vector Manufacturing Market for Clinical Scale: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
19.3.3. Adeno-associated Virus Vector Manufacturing Market for Preclinical Scale: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
19.4. Data Triangulation and Validation
20. ADENO-ASSOCIATED VIRUS VECTOR MANUFACTURING MARKET, BY TYPE OF MANUFACTURER
20.1. Chapter Overview
20.2. Assumptions and Methodology
20.3. Adeno-associated Virus Vector Manufacturing Market: Distribution by Type of Manufacturer
20.3.1. Adeno-associated Virus Vector Manufacturing Market for Contract Manufacturers: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
20.3.2. Adeno-associated Virus Vector Manufacturing Market for In-house Manufacturers: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
20.4. Data Triangulation and Validation
21. ADENO-ASSOCIATED VIRUS VECTOR MANUFACTURING MARKET, BY THERAPEUTIC AREA
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Adeno-associated Virus Vector Manufacturing Market: Distribution by Therapeutic Area
21.3.1. Adeno-associated Virus Vector Manufacturing Market for Oncological Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
21.3.2. Adeno-associated Virus Vector Manufacturing Market for Rare Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
21.3.3. Adeno-associated Virus Vector Manufacturing Market for Immunological Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
21.3.4. Adeno-associated Virus Vector Manufacturing Market for Neurological Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
21.3.5. Adeno-associated Virus Vector Manufacturing Market for Sensory Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
21.3.6. Adeno-associated Virus Vector Manufacturing Market for Metabolic Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
21.3.7. Adeno-associated Virus Vector Manufacturing Market for Blood Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
21.3.8. Adeno-associated Virus Vector Manufacturing Market for Musculoskeletal Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
21.3.9. Adeno-associated Virus Vector Manufacturing Market for Infectious Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
21.3.10. Adeno-associated Virus Vector Manufacturing Market for Ophthalmic Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
21.3.11. Adeno-associated Virus Vector Manufacturing Market for Other Disorders: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
21.4. Data Triangulation and Validation
22. ADENO-ASSOCIATED VIRUS VECTOR MANUFACTURING MARKET, BY GEOGRAPHICAL REGIONS
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Adeno-associated Virus Vector Manufacturing Market: Distribution by Geographical Regions
22.3.1. Adeno-associated Virus Vector Manufacturing Market in North America: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
22.3.2. Adeno-associated Virus Vector Manufacturing Market in Europe: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
22.3.3. Adeno-associated Virus Vector Manufacturing Market in Asia-Pacific: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
22.3.4. Adeno-associated Virus Vector Manufacturing Market in Rest of the World: Historical Trends (since 2023) and Forecasted Estimates (till 2035)
22.4. Market Dynamics Assessment
22.4.1. Penetration Growth (P-G) Matrix
22.5. Data Triangulation and Validation
23. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA
23.1. Adeno-associated Virus Vector Manufacturing Market in North America: Distribution by Scale of Operation
23.1.1. Adeno-associated Virus Vector Manufacturing Market in North America for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
23.1.2. Adeno-associated Virus Vector Manufacturing Market in North America for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
23.1.3. Adeno-associated Virus Vector Manufacturing Market in North America for Preclinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
23.2. Adeno-associated Virus Vector Manufacturing Market in North America: Distribution by Type of Manufacturer
23.2.1. Adeno-associated Virus Vector Manufacturing Market in North America for Contract Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
23.2.2. Adeno-associated Virus Vector Manufacturing Market in North America for In-house Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
23.3. Adeno-associated Virus Vector Manufacturing Market in North America: Distribution by Therapeutic Area
23.3.1. Adeno-associated Virus Vector Manufacturing Market in North America for Oncological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
23.3.2. Adeno-associated Virus Vector Manufacturing Market in North America for Rare Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
23.3.3. Adeno-associated Virus Vector Manufacturing Market in North America for Immunological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
23.3.4. Adeno-associated Virus Vector Manufacturing Market in North America for Neurological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
23.3.5. Adeno-associated Virus Vector Manufacturing Market in North America for Sensory Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
23.3.6. Adeno-associated Virus Vector Manufacturing Market in North America for Metabolic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
23.3.7. Adeno-associated Virus Vector Manufacturing Market in North America for Blood Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
23.3.8. Adeno-associated Virus Vector Manufacturing Market in North America for Musculoskeletal Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
23.3.9. Adeno-associated Virus Vector Manufacturing Market in North America for Infectious Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
23.3.10. Adeno-associated Virus Vector Manufacturing Market in North America for Ophthalmic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
23.3.11. Adeno-associated Virus Vector Manufacturing Market in North America for Other Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24. MARKET OPPORTUNITY ANALYSIS: EUROPE
24.1. Adeno-associated Virus Vector Manufacturing Market in Europe: Distribution by Scale of Operation
24.1.1. Adeno-associated Virus Vector Manufacturing Market in Europe for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.1.2. Adeno-associated Virus Vector Manufacturing Market in Europe for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.1.3. Adeno-associated Virus Vector Manufacturing Market in Europe for Preclinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.2. Adeno-associated Virus Vector Manufacturing Market in Europe: Distribution by Type of Manufacturer
24.2.1. Adeno-associated Virus Vector Manufacturing Market in Europe for Contract Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.2.2. Adeno-associated Virus Vector Manufacturing Market in Europe for In-house Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.3. Adeno-associated Virus Vector Manufacturing Market in Europe: Distribution by Therapeutic Area
24.3.1. Adeno-associated Virus Vector Manufacturing Market in Europe for Oncological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.3.2. Adeno-associated Virus Vector Manufacturing Market in Europe for Rare Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.3.3. Adeno-associated Virus Vector Manufacturing Market in Europe for Immunological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.3.4. Adeno-associated Virus Vector Manufacturing Market in Europe for Neurological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.3.5. Adeno-associated Virus Vector Manufacturing Market in Europe for Sensory Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.3.6. Adeno-associated Virus Vector Manufacturing Market in Europe for Metabolic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.3.7. Adeno-associated Virus Vector Manufacturing Market in Europe for Blood Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.3.8. Adeno-associated Virus Vector Manufacturing Market in Europe for Musculoskeletal Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.3.9. Adeno-associated Virus Vector Manufacturing Market in Europe for Infectious Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.3.10. Adeno-associated Virus Vector Manufacturing Market in Europe for Ophthalmic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
24.3.11. Adeno-associated Virus Vector Manufacturing Market in Europe for Other Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
25. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC
25.1. Adeno-associated Virus Vector Manufacturing Market in Asia-Pacific: Distribution by Scale of Operation
25.1.1. Adeno-associated Virus Vector Manufacturing Market in Asia-Pacific for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
25.1.2. Adeno-associated Virus Vector Manufacturing Market in Asia-Pacific for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
25.1.3. Adeno-associated Virus Vector Manufacturing Market in Asia-Pacific for Preclinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
25.2. Adeno-associated Virus Vector Manufacturing Market in Asia-Pacific: Distribution by Type of Manufacturer
25.2.1. Adeno-associated Virus Vector Manufacturing Market in Asia-Pacific for Contract Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
25.2.2. Adeno-associated Virus Vector Manufacturing Market in Asia-Pacific for In-house Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
25.3. Adeno-associated Virus Vector Manufacturing Market in Asia-Pacific: Distribution by Therapeutic Area
25.3.1. Adeno-associated Virus Vector Manufacturing Market in Asia-Pacific for Oncological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
25.3.2. Adeno-associated Virus Vector Manufacturing Market in Asia-Pacific for Rare Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
25.3.3. Adeno-associated Virus Vector Manufacturing Market in Asia-Pacific for Immunological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
25.3.4. Adeno-associated Virus Vector Manufacturing Market in Asia-Pacific for Neurological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
25.3.5. Adeno-associated Virus Vector Manufacturing Market in Asia-Pacific for Sensory Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
25.3.6. Adeno-associated Virus Vector Manufacturing Market in Asia-Pacific for Metabolic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
25.3.7. Adeno-associated Virus Vector Manufacturing Market in Asia-Pacific for Blood Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
25.3.8. Adeno-associated Virus Vector Manufacturing Market in Asia-Pacific for Musculoskeletal Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
25.3.9. Adeno-associated Virus Vector Manufacturing Market in Asia-Pacific for Infectious Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
25.3.10. Adeno-associated Virus Vector Manufacturing Market in Asia-Pacific for Ophthalmic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
25.3.11. Adeno-associated Virus Vector Manufacturing Market in Asia-Pacific for Other Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
26. MARKET OPPORTUNITY ANALYSIS: REST OF THE WORLD
26.1. Adeno-associated Virus Vector Manufacturing Market in Rest of the World: Distribution by Scale of Operation
26.1.1. Adeno-associated Virus Vector Manufacturing Market in Rest of the World for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
26.1.2. Adeno-associated Virus Vector Manufacturing Market in Rest of the World for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
26.1.3. Adeno-associated Virus Vector Manufacturing Market in Rest of the World for Preclinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
26.2. Adeno-associated Virus Vector Manufacturing Market in Rest of the World: Distribution by Type of Manufacturer
26.2.1. Adeno-associated Virus Vector Manufacturing Market in Rest of the World for Contract Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
26.2.2. Adeno-associated Virus Vector Manufacturing Market in Rest of the World for In-house Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
26.3. Adeno-associated Virus Vector Manufacturing Market in Rest of the World: Distribution by Therapeutic Area
26.3.1. Adeno-associated Virus Vector Manufacturing Market in Rest of the World for Oncological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
26.3.2. Adeno-associated Virus Vector Manufacturing Market in Rest of the World for Rare Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
26.3.3. Adeno-associated Virus Vector Manufacturing Market in Rest of the World for Immunological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
26.3.4. Adeno-associated Virus Vector Manufacturing Market in Rest of the World for Neurological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
26.3.5. Adeno-associated Virus Vector Manufacturing Market in Rest of the World for Sensory Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
26.3.6. Adeno-associated Virus Vector Manufacturing Market in Rest of the World for Metabolic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
26.3.7. Adeno-associated Virus Vector Manufacturing Market in Rest of the World for Blood Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
26.3.8. Adeno-associated Virus Vector Manufacturing Market in Rest of the World for Musculoskeletal Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
26.3.9. Adeno-associated Virus Vector Manufacturing Market in Rest of the World for Infectious Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
26.3.10. Adeno-associated Virus Vector Manufacturing Market in Rest of the World for Ophthalmic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
26.3.11. Adeno-associated Virus Vector Manufacturing Market in Rest of the World for Other Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
27. CONCLUDING INSIGHTS
28. EXECUTIVE INSIGHTS
29. APPENDIX I: TABULATED DATA
30. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Classification of Vectors
Figure 6.2 Structure of Adeno-associated Virus Vector
Figure 6.3 Lytic Cycle of Adeno-associated Virus Vector
Figure 6.4 Lysogenic Cycle of Adeno-associated Virus Vector
Figure 7.1 Adeno-associated Virus Vector Manufacturers: Distribution by Year of Establishment
Figure 7.2 Adeno-associated Virus Vector Manufacturers: Distribution by Company Size
Figure 7.3 Adeno-associated Virus Vector Manufacturers: Distribution by Location of Headquarters
Figure 7.4 Adeno-associated Virus Vector Manufacturers: Distribution by Type of Product Manufactured
Figure 7.5 Adeno-associated Virus Vector Manufacturers: Distribution by Type of Vector Manufactured
Figure 7.6 Adeno-associated Virus Vector Manufacturers: Distribution by Scale of Operation
Figure 7.7 Adeno-associated Virus Vector Manufacturers: Distribution by Type of Manufacturer
Figure 7.8 Adeno-associated Virus Vector Manufacturers: Distribution by Application Area
Figure 7.9 Adeno-associated Virus Vector Manufacturers: Distribution by Location of Manufacturing Facility
Figure 8.1 Adeno-associated Virus Vector Manufacturing Technologies / Platforms: Distribution by Type of Vector Manufactured
Figure 8.2 Adeno-associated Virus Vector Manufacturing Technologies / Platforms: Distribution by Type of Virus Vector Manufactured
Figure 8.3 Adeno-associated Virus Vector Manufacturing Technologies / Platforms: Distribution by Scale of Operation
Figure 8.4 Adeno-associated Virus Vector Manufacturing Technologies / Platforms: Distribution by End-use
Figure 8.5 Adeno-associated Virus Vector Technology / Platform Providers: Distribution by Year of Establishment
Figure 8.6 Adeno-associated Virus Vector Technology Platform Providers: Distribution by Company Size
Figure 8.7 Adeno-associated Virus Vector Technology / Platform Providers: Distribution by Location of Headquarters
Figure 8.8 Most Active Players: Distribution by Number of Technologies / Platforms
Figure 9.1 Company Competitiveness Analysis: Overview of Peer Group I
Figure 9.2 Company Competitiveness Analysis: Overview of Peer Group II
Figure 9.3 Company Competitiveness Analysis: Overview of Peer Group III
Figure 9.4 Company Competitiveness Analysis: Adeno-associated Virus Vector Manufacturers Headquartered in North America (Peer Group I)
Figure 9.5 Company Competitiveness Analysis: Adeno-associated Virus Vector Manufacturers Headquartered in Europe (Peer Group II)
Figure 9.6 Company Competitiveness Analysis: Adeno-associated Virus Vector Manufacturers Headquartered in Asia-Pacific (Peer Group III)
Figure 10.1 Technology Competitiveness Analysis: Overview of Peer Group I
Figure 10.2 Technology Competitiveness Analysis: Overview of Peer Group II
Figure 10.3 Technology Competitiveness Analysis: Overview of Peer Group III
Figure 10.4 Technology Competitiveness Analysis: Adeno-associated Virus Vector Technologies / Platforms Provided by Companies Headquartered in North America (Peer Group I)
Figure 10.5 Technology Competitiveness Analysis: Adeno-associated Virus Vector Technologies / Platforms Provided by Companies Headquartered in Europe (Peer Group II)
Figure 10.6 Technology Competitiveness Analysis: Adeno-associated Virus Vector Technologies / Platforms Provided by Companies Headquartered in Asia-Pacific (Peer Group III)
Figure 12.1 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, since 2020
Figure 12.2 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Registration Year, since 2020
Figure 12.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 12.4 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Phase
Figure 12.5 Clinical Trial Analysis: Distribution by Trial Status
Figure 12.6 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Status
Figure 12.7 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status
Figure 12.8 Clinical Trial Analysis: Distribution by Target Patient Population
Figure 12.9 Clinical Trial Analysis: Distribution by Patient Gender
Figure 12.10 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 12.11 Clinical Trial Analysis: Distribution by Type of Patient Allocation Model Used
Figure 12.12 Clinical Trial Analysis: Distribution by Type of Trial Masking Adopted
Figure 12.13 Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 12.14 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 12.15 Most Active Industry Players: Distribution by Number of Clinical Trials Sponsored / Collaborated
Figure 12.16 Most Active Non-Industry Players: Distribution by Number of Clinical Trials Sponsored / Collaborated
Figure 12.17 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 12.18 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Figure 12.19 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Figure 12.20 Clinical Trial Analysis: Distribution of Clinical Trials by Geography, Trial Status and Trial Phase
Figure 13.1 Adeno-associated Virus Vector Manufacturers: Cumulative Year-wise Trend, Since pre-2021
Figure 13.2 Adeno-associated Virus Vector Manufacturers: Distribution by Type of Partnership
Figure 13.3 Adeno-associated Virus Vector Manufacturers: Distribution by Year and Type of Partnership, Since pre-2021
Figure 13.4 Adeno-associated Virus Vector Manufacturers: Distribution by Type of Partner
Figure 13.5 Adeno-associated Virus Vector Manufacturers: Distribution by Scale of Operation
Figure 13.6 Adeno-associated Virus Vector Manufacturers: Distribution by Therapeutic Area
Figure 13.7 Adeno-associated Virus Vector Manufacturers: Distribution by Application Area
Figure 13.8 Most Active Players: Distribution by Number of Partnerships
Figure 13.9 Adeno-associated Virus Vector Manufacturers: Local and International Agreements
Figure 13.10 Adeno-associated Virus Vector Manufacturers: Intracontinental and Intercontinental Agreements
Figure 14.1 Patent Analysis: Distribution by Type of Patent
Figure 14.2 Patent Analysis: Distribution by Patent Application Year, since Pre-2019
Figure 14.3 Patent Analysis: Distribution by Publication Year, since 2021
Figure 14.4 Patent Analysis: Type of Patent and Publication Year, since 2021
Figure 14.5 Patent Analysis: Distribution by Patent Jurisdiction
Figure 14.6 Patent Analysis: Distribution by CPC Symbols
Figure 14.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, since 2021
Figure 14.8 Leading Industry Players: Distribution by Number of Patents
Figure 14.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 14.10 Leading Patent Assignees: Distribution by Number of Patents
Figure 14.11 Patent Benchmarking Analysis: Distribution by Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 14.12 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 14.13 Patent Valuation: Distribution of Patents by Age
Figure 14.14 AAV Vector Market: Patent Valuation
Figure 15.1 Start-up Health Indexing: Distribution by Location of Headquarters
Figure 15.2 Start-up Health Indexing: Distribution by Pipeline Strength
Figure 15.3 Start-up Health Indexing: Distribution by Pipeline Maturity
Figure 15.4 Start-up Health Indexing: Distribution by Indication Diversity
Figure 15.5 Start-up Health Indexing: Distribution by Patent Strength
Figure 15.6 Start-up Health Indexing: Distribution by Partnership Activity
Figure 15.7 Start-up Health Indexing: Roots Analysis Perspective
Figure 15.8 Leading Start-ups: Spider Web Analysis
Figure 16.1 Outsourcing: Go / No Go Framework
Figure 16.2 Outsourcing: Go / No Go Framework for Adeno-associated Virus Vector Based Therapy Developers
Figure 16.3 Adeno-associated Virus Vector Based Therapy Developers: Benchmarking of Small Companies
Figure 16.4 Adeno-associated Virus Vector Based Therapy Developers: Benchmarking of Mid-sized Companies
Figure 16.5 Adeno-associated Virus Vector Based Therapy Developers: Benchmarking of Large Companies
Figure 18.1 Global Adeno associated Virus Vector Manufacturing Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.2 Global Adeno associated Virus Vector Manufacturing Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
Figure 18.3 Global Adeno associated Virus Vector Manufacturing Market Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
Figure 19.1 Adeno associated Virus Vector Manufacturing Market: Distribution by Scale of Operation
Figure 19.2 Adeno associated Virus Vector Manufacturing Market for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 19.3 Adeno associated Virus Vector Manufacturing Market for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 19.4 Adeno associated Virus Vector Manufacturing Market for Preclinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 20.1 Adeno associated Virus Vector Manufacturing Market: Distribution by Type of Manufacturer
Figure 20.2 Adeno associated Virus Vector Manufacturing Market for Contract Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 20.3 Adeno associated Virus Vector Manufacturing Market for In-house Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.1 Adeno associated Virus Vector Manufacturing Market: Distribution by Therapeutic Area
Figure 21.2 Adeno associated Virus Vector Manufacturing Market for Oncological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.3 Adeno associated Virus Vector Manufacturing Market for Rare Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.4 Adeno associated Virus Vector Manufacturing Market for Immunological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.5 Adeno associated Virus Vector Manufacturing Market for Neurological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.6 Adeno associated Virus Vector Manufacturing Market for Sensory Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.7 Adeno associated Virus Vector Manufacturing Market for Metabolic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.8 Adeno associated Virus Vector Manufacturing Market for Blood Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.9 Adeno associated Virus Vector Manufacturing Market for Musculoskeletal Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.10 Adeno associated Virus Vector Manufacturing Market for Infectious Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.11 Adeno associated Virus Vector Manufacturing Market for Ophthalmic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.12 Adeno associated Virus Vector Manufacturing Market for Other Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.1 Adeno associated Virus Vector Manufacturing Market: Distribution by Geographical Regions
Figure 22.2 Adeno associated Virus Vector Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.3 Adeno associated Virus Vector Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.4 Adeno associated Virus Vector Manufacturing Market in Asia-Pacific, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.5 Adeno associated Virus Vector Manufacturing Market in Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.6 Penetration Growth (P-G) Matrix
Figure 27.1 Concluding Remarks: Adeno-Associated Virus Vector Based Manufacturers and Technologies / Platforms Landscape
Figure 27.2 Concluding Remarks: Clinical Trial Analysis
Figure 27.3 Concluding Remarks: Partnerships and Collaborations
Figure 27.4 Concluding Remarks: Patent Analysis
Figure 27.5 Concluding Remarks: Adeno-Associated Virus Vector Manufacturing Market Forecast
Table 7.1 Adeno-associated Virus Vector Manufacturers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 7.2 Adeno-associated Virus Vector Manufacturers: Information on Type of Product Manufactured and Type of Vector Manufactured
Table 7.3 Adeno-associated Virus Vector Manufacturers: Information on Scale of Operation and Type of Manufacturer
Table 7.4 Adeno-associated Virus Vector Manufacturers: Information on Application Area and Location of Manufacturing Facility
Table 8.1 Adeno-associated Virus Vector Manufacturing Technologies / Platforms: Information on Technology Provider, Type of Vector Manufactured and Type of Virus Vector Manufactured
Table 8.2 Adeno-associated Virus Vector Manufacturing Technologies / Platforms: Information on Scale of Operation and End-use
Table 8.3 Adeno-associated Virus Vector Manufacturing Technology / Platform Providers: Information on Year of Establishment, Company Size and Headquarters
Table 11.1 AAV Vector Manufacturers: List of Companies Profiled
Table 11.2 Astellas Pharma: Company Overview
Table 11.3 Astellas Pharma: Vector Manufacturing Portfolio
Table 11.4 Charles River Laboratories: Company Overview
Table 11.5 Charles River Laboratories: Vector Manufacturing Portfolio
Table 11.6 Cytiva: Company Overview
Table 11.7 Cytiva: Vector Manufacturing Portfolio
Table 11.8 Lonza: Company Overview
Table 11.9 Cytiva: Vector Manufacturing Portfolio
Table 11.10 Novartis Gene Therapies: Company Overview
Table 11.11 Novartis Gene Therapies: Vector Manufacturing Portfolio
Table 11.12 Sanofi: Company Overview
Table 11.13 Sanofi: Vector Manufacturing Portfolio
Table 11.14 Thermo Fisher Scientific: Company Overview
Table 11.15 WuXi AppTec: Vector Manufacturing Portfolio
Table 11.16 WuXi AppTec: Company Overview
Table 11.17 WuXi AppTec: Vector Manufacturing Portfolio
Table 13.1 Adeno-associated Virus Vector Manufacturers: List of Partnerships and Collaborations, Since 2017
Table 13.2 Adeno-associated Virus Vector Manufacturers: Information on Type of Partner and Scale of Operation
Table 13.3 Adeno-associated Virus Vector Manufacturers: Information on Therapeutic Area and Application Area
Table 14.1 Patent Analysis: Top CPC Sections
Table 14.2 Patent Analysis: Top CPC Symbols
Table 14.3 Patent Analysis: Top CPC Codes
Table 14.4 Patent Analysis: Summary of Benchmarking Analysis
Table 14.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 14.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 14.7 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 15.1 List of Start-ups Developing Adeno-associated Virus Vectors
Table 28.1 Andelyn Bioscience: Organization Snapshot
Table 28.2 University of Florida: Organization Snapshot
Table 28.3 Boston College: Organization Snapshot
Table 29.1 Adeno-associated Virus Vector Manufacturers: Distribution by Year of Establishment
Table 29.2 Adeno-associated Virus Vector Manufacturers: Distribution by Company Size
Table 29.3 Adeno-associated Virus Vector Manufacturers: Distribution by Location of Headquarters (Region)
Table 29.4 Adeno-associated Virus Vector Manufacturers: Distribution by Type of Product Manufactured
Table 29.5 Adeno-associated Virus Vector Manufacturers: Distribution by Type of Vector Manufactured
Table 29.6 Adeno-associated Virus Vector Manufacturers: Distribution by Scale of Operation
Table 29.7 Adeno-associated Virus Vector Manufacturers: Distribution by Type of Manufacturer
Table 29.8 Adeno-associated Virus Vector Manufacturers: Distribution by Application Area
Table 29.9 Adeno-associated Virus Vector Manufacturers: Distribution by Location of Manufacturing Facilities (Region)
Table 29.10 Adeno-associated Virus Vector Manufacturing Technologies / Platforms: Distribution by Type of Vector Manufactured
Table 29.11 Adeno-associated Virus Vector Manufacturing Technologies / Platforms: Distribution by Type of Virus Vector Manufactured
Table 29.12 Adeno-associated Virus Vector Manufacturing Technologies / Platforms: Distribution by Scale of Operation
Table 29.13 Adeno-associated Virus Vector Manufacturing Technologies / Platforms: Distribution by End-use
Table 29.14 Adeno-associated Virus Vector Technology / Platform Providers: Distribution by Year of Establishment
Table 29.15 Adeno-associated Virus Vector Technology / Platform Providers: Distribution by Company Size
Table 29.16 Adeno-associated Virus Vector Technology / Platform Providers: Distribution by Location of Headquarters (Region)
Table 29.17 Most Active Players: Distribution by Number of Technologies / Platforms
Table 29.18 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Registration Year, Since 2020
Table 29.19 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Registration Year, since 2020
Table 29.20 Clinical Trial Analysis: Distribution by Trial Phase
Table 29.21 Clinical Trial Analysis: Distribution by Trial Phase and Number of Patients Enrolled
Table 29.22 Clinical Trial Analysis: Distribution by Trial Status
Table 29.23 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Status
Table 29.24 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Trial Status
Table 29.25 Clinical Trial Analysis: Distribution by Target Patient Population
Table 29.26 Clinical Trial Analysis: Distribution by Patient Gender
Table 29.27 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 29.28 Clinical Trial Analysis: Distribution by Type of Patient Allocation Model Used
Table 29.29 Clinical Trial Analysis: Distribution by Type of Trial Masking Adopted
Table 29.30 Clinical Trial Analysis: Distribution by Type of Intervention Model
Table 29.31 Clinical Trial Analysis: Distribution by Trial Purpose
Table 29.32 Most Active Industry Players: Distribution by Number of Clinical Trials Sponsored
Table 29.33 Most Active Non-Industry Players: Distribution by Number of Clinical Trials Sponsored
Table 29.34 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 29.35 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Table 29.36 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Table 29.37 Clinical Trial Analysis: Distribution of Clinical Trials by Geography, Trial Status and Trial Phase
Table 29.38 Adeno-associated Virus Vector Manufacturers: Cumulative Year-wise Trend, Since pre-2021
Table 29.39 Adeno-associated Virus Vector Manufacturers: Distribution by Type of Partnership
Table 29.40 Adeno-associated Virus Vector Manufacturers: Distribution by Year of Partnership and Type of Partnership, Since pre-2021
Table 29.41 Adeno-associated Virus Vector Manufacturers: Distribution by Type of Partner
Table 29.42 Adeno-associated Virus Vector Manufacturers: Distribution by Scale of Operation
Table 29.43 Adeno-associated Virus Vector Manufacturers: Distribution by Therapeutic Area
Table 29.44 Adeno-associated Virus Vector Manufacturers: Distribution by Application Area
Table 29.45 Most Active Players: Distribution by Number of Partnerships
Table 29.46 Adeno-associated Virus Vector Manufacturers: Local and International Agreements
Table 29.47 Adeno-associated Virus Vector Manufacturers: Intracontinental and Intercontinental Agreements
Table 29.48 Patent Analysis: Distribution by Type of Patent
Table 29.49 Patent Analysis: Distribution by Patent Application Year, since Pre-2019-2025
Table 29.50 Patent Analysis: Distribution by Publication Year, since 2021
Table 29.51 Patent Analysis: Type of Patent and Publication Year
Table 29.52 Patent Analysis: Distribution by Patent Jurisdiction
Table 29.53 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, since 2021
Table 29.54 Leading Industry Players: Distribution by Number of Patents
Table 29.55 Leading Non-Industry Players: Distribution by Number of Patents
Table 29.56 Leading Patent Assignees: Distribution by Number of Patents
Table 29.57 Patent Valuation: Distribution of Patents by Age
Table 29.58 Adeno-associated Virus Vectors: Patent Valuation
Table 29.59 Start-up Health Indexing: Distribution by Location of Headquarters
Table 29.60 Start-up Health Indexing: Distribution by Pipeline Strength
Table 29.61 Start-up Health Indexing: Distribution by Pipeline Maturity
Table 29.62 Start-up Health Indexing: Distribution by Indication Diversity
Table 29.63 Analysis of Start-ups: Distribution by Patent Strength
Table 29.64 Start-up Health Indexing: Distribution by Partnership Activity
Table 29.65 Global Adeno associated Virus Vector Manufacturing Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 29.66 Global Adeno associated Virus Vector Manufacturing Market, Forecasted Estimates (till 2035), Conservative Scenario (USD Million)
Table 29.67 Global Adeno associated Virus Vector Manufacturing Market Forecasted Estimates (till 2035) Optimistic Scenario (USD Million)
Table 29.68 Adeno associated Virus Vector Manufacturing Market: Distribution by Scale of Operation
Table 29.69 Adeno associated Virus Vector Manufacturing Market for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 29.70 Adeno associated Virus Vector Manufacturing Market for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 29.71 Adeno associated Virus Vector Manufacturing Market for Preclinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 29.72 Adeno associated Virus Vector Manufacturing Market: Distribution Type of Manufacturer
Table 29.73 Adeno associated Virus Vector Manufacturing Market for Contract Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 29.74Adeno associated Virus Vector Manufacturing Market for In-house Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 29.74 Adeno associated Virus Vector Manufacturing Market: Distribution by Therapeutic Area
Table 29.75 Adeno associated Virus Vector Manufacturing Market for Oncological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 29.76 Adeno associated Virus Vector Manufacturing Market for Rare Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 29.77 Adeno associated Virus Vector Manufacturing Market for Immunological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 29.78 Adeno associated Virus Vector Manufacturing Market for Neurological Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 29.79 Adeno associated Virus Vector Manufacturing Market for Sensory Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 29.80 Adeno associated Virus Vector Manufacturing Market for Metabolic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 29.81 Adeno associated Virus Vector Manufacturing Market for Blood Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 29.82 Adeno associated Virus Vector Manufacturing Market for Musculoskeletal Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 29.83 Adeno associated Virus Vector Manufacturing Market for Infectious Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 29.84 Adeno associated Virus Vector Manufacturing Market for Ophthalmic Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 29.85 Adeno associated Virus Vector Manufacturing Market for Other Disorders, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 29.86 Adeno associated Virus Vector Manufacturing Market: Distribution by Geographical Regions
Table 29.87 Adeno associated Virus Vector Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 29.88 Adeno associated Virus Vector Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 29.89 Adeno associated Virus Vector Manufacturing Market in Asia-Pacific, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 29.90 Adeno associated Virus Vector Manufacturing Market in Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)